BACKGROUND: A randomised, unblinded, clinical trial comparing two benznidazole regimens for congenital Chagas disease was carried out to determine whether simplification and reduction in the length of treatment could lead to better treatment compliance. METHODS: This study was conducted in Santa Cruz, Bolivia. Serological screening was carried out in pregnant women, and parasites were sought in the blood of newborns from seropositive mothers. Infected infants were randomly assigned to two treatment groups. Recovery was assessed by parasite seeking at 1 month and 2 months as well as serological tests at 9 months. Assessment of treatment adherence was based on weekly home visits and use of electronic monitors. RESULTS:Benznidazole was given to 63 newborns in group A (5 mg/kg in two daily doses for 60 days) and 61 newborns in group B (7.5 mg/kg in a single daily dose for 30 days). There was no difference in compliance between the two groups. The study confirmed the efficacy and good tolerance of both benznidazole regimens in the treatment of congenital Chagas disease. CONCLUSIONS: The short treatment should be preferred as it allows reducing the dose of benznidazole as well as the cost of treatment.
RCT Entities:
BACKGROUND: A randomised, unblinded, clinical trial comparing two benznidazole regimens for congenital Chagas disease was carried out to determine whether simplification and reduction in the length of treatment could lead to better treatment compliance. METHODS: This study was conducted in Santa Cruz, Bolivia. Serological screening was carried out in pregnant women, and parasites were sought in the blood of newborns from seropositive mothers. Infected infants were randomly assigned to two treatment groups. Recovery was assessed by parasite seeking at 1 month and 2 months as well as serological tests at 9 months. Assessment of treatment adherence was based on weekly home visits and use of electronic monitors. RESULTS:Benznidazole was given to 63 newborns in group A (5 mg/kg in two daily doses for 60 days) and 61 newborns in group B (7.5 mg/kg in a single daily dose for 30 days). There was no difference in compliance between the two groups. The study confirmed the efficacy and good tolerance of both benznidazole regimens in the treatment of congenital Chagas disease. CONCLUSIONS: The short treatment should be preferred as it allows reducing the dose of benznidazole as well as the cost of treatment.
Authors: Sassan Noazin; Jessica A Lee; Edith S Malaga; Edward Valencia Ayala; Beth J Condori; Cristian Roca; Andres G Lescano; Caryn Bern; Walter Castillo; Holger Mayta; Maria Carmen Menduiña; Manuela R Verastegui; Freddy Tinajeros; Robert H Gilman Journal: J Infect Dis Date: 2019-01-29 Impact factor: 5.226
Authors: Louisa A Messenger; Robert H Gilman; Manuela Verastegui; Gerson Galdos-Cardenas; Gerardo Sanchez; Edward Valencia; Leny Sanchez; Edith Malaga; Victoria R Rendell; Malasa Jois; Vishal Shah; Nicole Santos; Maria Del Carmen Abastoflor; Carlos LaFuente; Rony Colanzi; Ricardo Bozo; Caryn Bern Journal: Clin Infect Dis Date: 2017-07-15 Impact factor: 9.079
Authors: Bernard Pecoul; Carolina Batista; Eric Stobbaerts; Isabella Ribeiro; Rafael Vilasanjuan; Joaquim Gascon; Maria Jesus Pinazo; Silvia Moriana; Silvia Gold; Ana Pereiro; Miriam Navarro; Faustino Torrico; Maria Elena Bottazzi; Peter J Hotez Journal: PLoS Negl Trop Dis Date: 2016-02-25